Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
16 sept. 2021 11h05 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
16 sept. 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
23 août 2021 16h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
12 août 2021 17h15 HE
|
Processa Pharmaceuticals, Inc.
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
06 août 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
04 août 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
27 juil. 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event...
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
06 juil. 2021 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation...
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
17 juin 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...
Processa Set to Join Russell Microcap® Index
08 juin 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...